ASX:CUVBiotechs
Clinuvel Pharmaceuticals (ASX:CUV) Is Up 5.9% After Dividend Hike and NASDAQ Plans Has The Bull Case Changed?
Clinuvel Pharmaceuticals recently announced its eighth consecutive annual dividend of A$0.05 per share, payable on September 19, 2025, following the release of robust full-year earnings showing revenue growth to A$105.3 million and net income of A$36.17 million for the year ended June 30, 2025.
This marks another step in Clinuvel’s international growth ambitions, with the company also progressing toward a Level II ADR listing on NASDAQ to enhance its presence in the U.S. market.
We'll...